Advancements in Intranasal Drug Delivery: Hovione and IDC Launch Commercial Platform

By João L. Carapinha

May 15, 2026

Hovione and IDC have announced that their Intranasal Drug Delivery platform has advanced to commercial readiness, with the lead single-use nasal dry powder device now available for partnerships. This integrated solution combines API development, particle engineering, formulation, capsule filling, and device supply, enabling partners to use existing infrastructure while cutting costs, risks, and development timelines.

Targeted Deposition for Systemic and Brain Delivery

The platform’s single-use device employs a patented mechanism for precise deposition across the nasal cavity, including the upper olfactory region, supporting rapid systemic absorption and potential nose-to-brain pathways. Early patent grants have been secured, and a multi-dose version is in development to expand use across therapies. This approach merges nasal particle engineering with manufacturing and device technologies, improving predictability for complex Intranasal Drug Delivery programs.

Efficient Manufacturing for Nasal Powders

Device design and initial manufacturing capabilities are complete, allowing partners to leverage existing capsule-filling lines without major new investment. Complementary in-vitro and analytical tools help address deposition, absorption, and retention challenges. These advances will be presented at the Respiratory Drug Delivery 2026 workshop, highlighting how combined expertise from Hovione and IDC reduces technology transfers and supports scalable production.

Lowering Barriers to Nasal Therapy Access

By simplifying development and manufacturing, the platform can accelerate commercialization of intranasal therapies and improve health-economic outcomes through greater efficiency and reliability. Hovione and IDC’s Intranasal Drug Delivery Platform offers a streamlined path that may enhance patient access and support stronger reimbursement positioning.

Reference url

Recent Posts

Portugal Cannabis Market Decline: Analyzing the Impact of Licensing Reductions

By João L. Carapinha

The Portugal cannabis market decline has accelerated sharply since January 2026. Official Infarmed IP lists show that more than 30 percent of entities authorised for medicinal cannabis activities in Portugal have been suspended or permanently removed, producing a measurable contraction across cul...
NICE Approves Durvalumab for Gastric Cancer Treatment

By HEOR Staff Writer

NICE has issued final draft guidance recommending durvalumab, within its marketing authorisation, for use with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by durvalumab monotherapy as adjuvant treatment, in adults with ...
Bladder Cancer Treatment Impact: Barriers to Quality of Life in Patients

By HEOR Staff Writer

A global survey highlights the profound bladder cancer treatment impact on patients with non-muscle-invasive bladder cancer, with more than 90 percent of those undergoing radical cystectomy or BCG therapy reporting negative physical, emotional, and mental health effects. Life-Altering Effect...